| Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders (NCT04485039) | SIGA Technologies | 2022-06-08 |
| Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS (NCT04957485) | SIGA Technologies | 2022-04-05 |
| Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days (NCT04971109) | SIGA Technologies | 2022-03-29 |
| Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years (NCT05846243) | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | 2021-10-01 |
| Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years (NCT05976100) | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | 2020-09-04 |
| A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox (NCT03972111) | SIGA Technologies | 2020-01-01 |
| Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG (NCT04392739) | SIGA Technologies | 2019-07-19 |
| Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial (NCT03699124) | Bavarian Nordic | 2019-06-19 |
| Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years (NCT05762523) | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | 2019-05-18 |
| A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat (NCT02474589) | SIGA Technologies | 2015-06-19 |
| Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection (NCT02038881) | Bavarian Nordic | 2014-04-28 |
| Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE® (NCT01827371) | National Institute of Allergy and Infectious Diseases (NIAID) | 2013-06-01 |
| A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects (NCT01668537) | Bavarian Nordic | 2013-03-01 |
| A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects (NCT01144637) | Bavarian Nordic | 2013-02-01 |
| Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally (NCT00914732) | National Institute of Allergy and Infectious Diseases (NIAID) | 2010-02-01 |
| Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers (NCT01056770) | Seoul National University Hospital | 2009-10-01 |
| Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel (NCT01540929) | Emergent BioSolutions | 2009-09-01 |
| A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects (NCT00857493) | Bavarian Nordic | 2009-06-01 |
| High Dose IMVAMUNE® in Vaccinia-Naive Individuals (NCT00879762) | National Institute of Allergy and Infectious Diseases (NIAID) | 2009-05-29 |
| Safety Surveillance Study of ACAM2000® Vaccinia Vaccine (NCT00927719) | Emergent BioSolutions | 2008-12-01 |
| Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®) (NCT00928577) | Emergent BioSolutions | 2008-12-01 |
| An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees (NCT00686582) | Bavarian Nordic | 2008-08-01 |
| Phase I Trial of an Investigational Small Pox Medication (NCT00728689) | SIGA Technologies | 2008-08-01 |
| Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study (NCT00646152) | National Institute of Allergy and Infectious Diseases (NIAID) | 2008-03-24 |
| Safety and Efficacy of CJ-50300 in Healthy Volunteers (NCT00607243) | Seoul National University Hospital | 2008-01-01 |
| MVA Post-Event: Administration Timing and Boost Study (NCT00437021) | National Institute of Allergy and Infectious Diseases (NIAID) | 2007-04-16 |
| Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD) (NCT00389103) | Sanofi Pasteur, a Sanofi Company | 2006-10-01 |
| A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain) (NCT00998543) | Sanofi | 2006-10-01 |
| Safety and Immunogenicity of CJ-50300 (NCT00336635) | Seoul National University Hospital | 2006-06-01 |
| A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects (NCT00316524) | Bavarian Nordic | 2006-04-01 |
| ACAM 3000 MVA at Harvard Medical School (NCT00133575) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-10-01 |
| Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults (NCT00258947) | Sanofi | 2005-09-01 |
| Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine (NCT00466245) | Sanofi Pasteur, a Sanofi Company | 2005-07-01 |
| Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers (NCT00103584) | VaxGen | 2004-10-01 |
| VHA Clinicians and Bioterror Events: Interactive Web-based Learning (NCT00123396) | US Department of Veterans Affairs | 2004-08-01 |
| Combination Study With MVA BN and Dryvax (NCT00082446) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-05-01 |
| Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults (NCT00079820) | Sanofi Pasteur, a Sanofi Company | 2004-04-01 |
| Dryvax Dilution-Prev Vacc Adults (NCT00032708) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-04-01 |
| Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects (NCT00189969) | Bavarian Nordic | 2003-09-01 |
| Dressing Preparations for Smallpox (NCT00063856) | National Institute of Allergy and Infectious Diseases (NIAID) | 2003-07-01 |
| Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine. (NCT00189956) | Bavarian Nordic | 2003-04-01 |
| Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination (NCT00053495) | Emergent BioSolutions | 2003-01-01 |
| Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults (NCT00053482) | Emergent BioSolutions | 2003-01-01 |
| Expanded Dryvax Dilution Study in Previously Vaccinated Adults (NCT00050505) | National Institute of Allergy and Infectious Diseases (NIAID) | 2002-10-01 |
| Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination (NCT00053508) | Sanofi Pasteur, a Sanofi Company | 2002-09-01 |
| Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT (NCT00038987) | National Institute of Allergy and Infectious Diseases (NIAID) | 2002-05-01 |
| A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults (NCT00026611) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Human Immune Responses Smallpox (NCT00068198) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure (NCT02080767) | U.S. Army Medical Research and Development Command | |
| APSV in Vaccinia Naive Adults (NCT00050518) | National Institute of Allergy and Infectious Diseases (NIAID) | |